Kornimate/medical-research-clean huggingface dataset:
safety study of kudiezi (a chinese medicine injection) used in hospitals in china

Conditions: Coronary Heart Disease; Angina Pectoris

Summary: this study was advocated by institute of basic research in clinical medicine, china academy of chinese medical sciences in october 2011. it was funded by china major scientific and technological specialized project for 'significant new formulation of new drugs'. kudiezi is kind of chinese medicine injection used for treating coronary heart disease and angina pectoris in many chinese hospitals. the purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.

it is very common that chinese medicine injection used in hospitals in mainland china. however safety problems rose in recent years. there could be many uncertain factors influence chinese medicine injection in clinical practice. safety surveillance on chinese medicine injection is an important problem that needs to be sorted out through large sample observational study. a registry study for kudiezi injection safety surveillance with 30000 patients will be conducted from jan.2012 to dec.2015. eligibility criteria patients who will use kudiezi injection in selected hospitals data will be collected in four aspects by four different forms as following: form a (blue): demographic information form b (yellow): adverse drug events/reaction form c (white): extracted information from hospital information system and laboratory information system form d (red): personalized information

Eligibility criteria:
inclusion criteria: * patients using kudiezi injection from 2012 to 2014 exclusion criteria: * none
the effect of virtual reality glasses on pain and anxiety

Conditions: Pain and Anxiety

Summary: in recent studies using virtual reality has been proposed as a non pharmacological methods for pain relief but until this time , its effects has not been assessed on pain and anxiety during episiotomy repair. to determine the effectiveness of virtual reality glasses on pain and anxiety in primiparity women during episiotomy repair.


Eligibility criteria:
inclusion criteria: * iranian * low risk pregnancy * apgar ≥ 7 exclusion criteria: * vision or ear disorders * history of motion sickness or headaches * psychological disease or addiction * prescribe narcotic or sedation 4hour prior to delivery.
a study of abt-165 plus folfiri vs bevacizumab plus folfiri in subjects with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin and bevacizumab

Conditions: Cancer

Summary: a study to evaluate the efficacy and tolerability of abt-165 plus folfiri compared to bevacizumab plus folfiri in participants with previously treated metastatic adenocarcinoma of the colon or rectum.


Eligibility criteria:
inclusion criteria: * diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum. * primary tumor has been resected \> 3 months prior to randomization. * at least 1 lesion on a computed tomography (ct) scan (preferred) or magnetic resonance imaging (mri) that is measurable as defined by response evaluation criteria in solid tumors (recist), version 1.1. * eastern cooperative oncology group (ecog) performance score of 0 or 1. * progression following treatment with fluoropyrimidine/oxaliplatin/bevacizumab-regimen in the metastatic setting. * adequate hematologic, renal and hepatic function. exclusion criteria: * any prior therapy with irinotecan * unresolved clinically significant toxicities from prior anticancer therapy, defined as any common terminology criteria for adverse events (ctcae) =\> grade 2 * clinically significant conditions that increase the risk for antiangiogenic therapy. * history of any of the following during first-line therapy with a bevacizumab-containing regimen: arterial thrombotic/thromboembolic event, bowel perforation, grade 4 hypertension, grade 3 proteinuria or grade 3 - 4 bleeding event.

Keywords: cancer colorectal cancer abt-165 folfiri bevacizumab bowel cancer metastatic colorectal cancer metastatic colorectal
a prospective study of factors related to exacerbation and mortality of non-cystic fibrosis bronchiectasis in hong kong

Conditions: Bronchiectasis Adult

Summary: bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. in a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older 2. clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of exacerbation, no requirement for supplemental antibiotic therapy) 3. diagnosis of bronchiectasis defined by high-resolution computed tomography scan exclusion criteria: 1. history of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary aspergilosis 2. those who are unable to give consent
evaluation of a new open source virtual bronchoscope navigation system

Conditions: Bronchial Neoplasms

Summary: to evaluate the feasibility of the fraxinus virtual bronchoscope navigation (vbn) system in the bronchoscopic access to target lesions. the study emphasizes the system´s efficacy in diagnostics of peripheral pulmonary lesions and the ease of use for the operator.

multi-center study. the study explores fraxinus which is an open source, software only, simple guiding system for bronchoscopy. the system provides 3d maps with centerline-to-target information extracted from preoperative computed tomography. the ability of the system to guide a user to a peripheral target lesion will be evaluated. during bronchoscopy any established method for diagnostic sampling is allowed. user evaluation will be essential to decide if the fraxinus vbn system is beneficial in a clinical setting.

Eligibility criteria:
inclusion criteria: * referred to thoracic department in any of the participating hospitals with undiagnosed peripheral pulmonary lesion(s) not visible by bronchoscopy * voluntary signed an informed consent exclusion criteria: * pregnancy * any patient that the investigator feels is not appropriate for this study for any reason

Keywords: bronchoscopy navigation feasibility studies
comparing praziquantel versus artesunate + sulfamethoxypyrazine/pyrimethamine for treating schistosomiasis

Conditions: Schistosoma Haematobium

Summary: the purpose of this study is to evaluate the efficacy of praziquantel versus as+smp (co-arinate fdc ®) in the treatment of schistosoma haematobium in 6-15 year old malian children. the nul-hypothesis in this study is that the combination of as+smp is more effective than praziquantel in the treatment of s. haematobium infected children.


Eligibility criteria:
inclusion criteria: * aged between 6-15 years * in good health, according to study doctor * suffering from urinary schistosomiasis, as diagnosed by the presence of s. haematobium eggs in the urine. * residents of djalakorodji * capable of taking oral medication * written informed consent to participate in the study, obtained from parent or legal guardian. exclusion criteria: * weighing more than 50 kg * being pregnant or lactating at the time of the study * patient has a severe concomitant disease, as determined by the clinical examination, such as cerebral cysticercosis, hiv,... * signs of severe malnutrition (children weighing/measuring more than 3 standard deviations or less than 70% of the median standard reference values determined by who, or with systemic oedema affecting both feet). * hypersensitivity to as, smp or pzq * having taken other antimalarial or antischistosomal medication during the study. * having participated in previous similar studies

Keywords: schistosoma haematobium praziquantel artesunate + sulfamethoxypyrazine/pyrimethamine randomized double blind placebo controlled clinical trial
periodontal dressing after surgical crown lengthening

Conditions: Pain; Wound Healing Disturbance of; Periodontal Infection

Summary: background: there is controversy regarding the postoperative effects of periodontal dressing on the periodontium, pain and discomfort. the aim of the present study was to compare postoperative pain following surgical crown lengthening with and without the use of periodontal dressing. material and methods: a blind, randomized, clinical trial was carried out with 36 patients. following surgical crown lengthening, the individuals were randomly allocated to the periodontal dressing group (pdg) and control group (cg - non-placement of periodontal dressing). pain and discomfort were analyzed using a visual analog scale (vas), verbal scale (vs) and the number of analgesics consumed in seven days postoperatively. postoperative infection, stability of the gingival margin and type of healing were also evaluated.


Eligibility criteria:
inclusion criteria: * need for surgical crown lengthening on only one tooth with need for proximal osteotomy; * aged 18 years or older; * absence of systemic disease; * absence of periodontal disease at the site of surgical crown lengthening; * no restrictions regarding the procedure; * no need for antimicrobial prophylaxis. exclusion criteria: * failure to return for the postoperative evaluations; * failure to fill out the charts correctly; * occurrence of pulp alteration in the operated tooth following the procedure; * occurrence of partial or total loss of the periodontal dressing; * allergic reaction to periodontal dressing.

Keywords: periodontal dressings surgical crown lengthening periodontal surgery
the cooking for health optimization and disease prevention (chop) trial

Conditions: Cardiovascular Diseases

Summary: poor nutrition-related diseases disproportionately impact seniors and racial/ethnic minorities who are more likely to experience disparities in proper nutrition. culinary medicine is a new evidence-based educational approach that blends the art of food and cooking with the science of medicine. recently, culinary medicine is proposed by the 2020-2030 strategic plan for nih nutrition research and national 'food is medicine (fim)' movement as potential solutions for improving healthy eating, creating social and emotional connections, and nutrition-related health equity. built upon the well-established community teaching kitchen at the goldring center for culinary medicine (gccm) at tulane university and nearly 10 years of experience in delivering culinary education of mediterranean diet (meddiet), the investigators will conduct a randomized controlled trial (rct) to test the feasibility and effectiveness of 3-month community teaching kitchen-based culinary education of meddiet on improving cardiometabolic and mental health among racially and ethnically diverse seniors.

the study is designed as a two-arm parallel-group randomized controlled trial (rct). the interventions in the two groups are described as below: i) culinary intervention group (n=48): the interventions include the teaching-kitchen based structured, hands-on culinary education classes. ii) usual diet control group (n=48): participants randomized to the usual diet group will not receive culinary education classes, while they will continue to receive clinical care recommendations from their physician(s).

Eligibility criteria:
inclusion criteria: * age 55 years or older * english speaking * ability to provide informed consent. exclusion criteria: * medical history of cardiovascular disease (cvd) or cancer. * food allergies including, but not limited to, milk, eggs, shellfish, nuts, wheat or gluten, and soy. * special diets including, but not limited to, mediterranean, veganism, vegetarianism, gluten-free, and the ketogenic diet. * current use of medications that could affect blood glucose and lipids levels including, but not limited to, insulins (humalog, novolog, insulin detemir, etc.), anti-diabetic medications (metformin, sulfonylureas, meglitinides, etc.), ozempic. haart, and beta blockers. * no children are involved. * no other vulnerable subjects will be involved.

Keywords: culinary cardiometabolic health mental health mediterranean diet nutrition
radial visualization of the foramen arcuale atlantis

Conditions: Patients With Kimmerle's Anomaly

Summary: hemodynamics in the craniovertebral zone is often disturbed under the influence of a spondylogenic factor a complication of such changes can be from a slight decrease in cerebral circulation to ischemic changes in the vascular bed the patients underwent complex radiation diagnostics of the craniovertebral region of patients with verified kimmerle's anomaly (n = 62) all examined patients underwent multispiral computed tomography (ct), ultrasound doppler and transcranial doppler (tcd) of the vertebral arteries (va) studies of the developmental variant of the first cervical vertebra with the presence of a bony bridge have shown that kimmerle's anomaly can occur in all age groups

the vaulted hole was found in all age groups (more in young and middle age) the detection rate was within 16 3% of cases, that is, it occurs in every 5-6 people according to tcd data, kimmerle's anomaly affects blood flow and was most often detected on both sides of the atlas in the unilateral variant, the anomaly was noted only on the left side it was found that the main structural change in the cerebral vascular bed, according to ultrasound diagnostics, is a change in the straightness of the vertebral arteries in the transverse processes of the cervical spine, including the atlas it should also be borne in mind that due to the complexity and mobility of the structure, patients with dysfunction of the craniovertebral zone receive therapy from doctors of various profiles, which requires a comprehensive diagnosis of this problem

Eligibility criteria:
inclusion criteria: * patients manifested themselves in the form of dizziness, various types of headache, mainly localized in the occipital region, nausea or flashing of flies before the eyes, in the rest - only cervicalgia exclusion criteria: * acute stroke, brain tumor

Keywords: kimmerle anomaly, vertebral artery, craniovertebral insufficiency, computed tomography, transcranial doppler
use of the swameco questionnaire basel

Conditions: Swallowing Difficulties

Summary: a patient self-report questionnaire was developed that assesses subjective swallowing difficulties with medication intake, the swameco questionnaire. it was validated in a highly specific population and will now be tested in the general population.

based on a systematic literature review, a novel self-report questionnaire was developed in 2016 to assess subjective swallowing difficulties with medication intake and their practical consequences in ambulatory patients, the swameco questionnaire. it consists of 30 items divided into 5 sections complaints, intensity, localization, coping strategies, and adherence to medication. it was validated in people suffering from systemic sclerosis (ssc), a rare multisystem autoimmune disease that often leads to swallowing problems with food and liquids with progression. the aim of this study is now to validate the questionnaire in the general population. patients presenting in the community pharmacy with a prescription of at least 3 different medications for a minimum of 3 months will fill in the questionnaire on site.

Eligibility criteria:
inclusion criteria: * aged 18 years or more * is living in the community setting * is receiving three or more medications for a period not less than three months, independently of the frequency of the intake exclusion criteria: * patients who are not able to provide written conformed consent will be excluded
safety and anti-inflammatory effect of sb681323 in patients with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease (COPD)

Summary: this is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of sb681323 in patients with copd (chronic obstructive pulmonary disease).


Eligibility criteria:
inclusion criteria: * non-childbearing potential. * clinical diagnosis of copd. * cigarette smoking history of greater than or equal to 10 pack years. * post-bronchodilator fev1 to fvc ratio (fev1:fvc) \< 0.7 * post-bronchodilator fev1 50% - 80% of predicted normal. * receiving inhaled corticosteroids for a minimum of 6 weeks prior to screening. * serum crp concentration greater than 3mg/l. exclusion criteria: * current diagnosis of asthma. * active tuberculosis, sarcoidosis or bronchiectasis. * history of any type of malignancy, rheumatoid arthritis or other conditions associated with chronic inflammation. * clinically significant renal or hepatic disease. * history of increased liver function tests, or patients receiving hormone replacement therapy, statins or systemic or topical corticosteroids.

Keywords: p38 map kinase crp copd safety
efficacy of pre-operative prehabilitation in patients with limb sarcoma

Conditions: Sarcoma

Summary: this phase ii feasibility study, prospective, interventional, monocentric aiming to assess the interest of pre-operative rehabilitation in patients treated for bone or soft-tissue sarcoma of the limbs. this protocol will be based on the realisation of a surgical prehabilitation program adapted to the patient. this strategy will involve a team of several health professionals: rehabilitation doctor, physiotherapist, occupational therapist, specialised nurse, dietician and adapted physical activity teacher. the aim of an adapted surgical prehabilitation program is to improve the functional recovery of the treated limb and the patient's autonomy after surgery. each patient will be followed until 24 months post surgery.


Eligibility criteria:
inclusion criteria: 1. age \> or = 16 years old. 2. patient with a diagnosis of bone or soft-tissue sarcoma confirmed by the "réseau de relecture en pathologie sarcomateuse (rreps)" 3. tumour localized in the lower or upper limb. 4. localized or metastatic disease (in case of metastatic disease, the optimal surgical treatment for the primary tumor must be performed). 5. indication of neoadjuvant treatment (radiotherapy and/or chemotherapy) according to the multidisciplinary concertation meeting. 6. inclusion before the initiation or during neoadjuvant treatment. in both cases, surgery must be scheduled between 6 and 10 weeks after inclusion, to permit the completion of the surgical prehabilitation. 7. patient must provide written informed consent prior to any study-specific procedure. for minor patients, the holder(s) of parental authority must sign the informed consent and the patient's assent must be obtained. 8. patient affiliated to the french social security system. exclusion criteria: 1. metastatic disease without optimal surgery planned of the primary tumour. 2. any disease or medical condition that could interfere with study procedure, or that could, according to the judgment of investigator, expose the patient to an unacceptable risk. 3. patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice). 4. any psychological, familial, geographic or social situation preventing compliance with the medical monitoring and/or with study procedure. 5. pregnant or breastfeeding patient.

Keywords: bone sarcoma soft-tissue sarcoma pre-operative prehabilitation
effect of simultaneous dual stimulation on freezing of gait in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to investigate the effect of dual-mode non-invasive brain stimulation (nibs) with high-frequency repetitive transcranial magnetic stimulation (rtms) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tdcs) over the left dorsolateral prefrontal cortex compared with rtms alone in patients with parkinson's disease (pd) with freezing of gait (fog).

patients in the dual-mode group underwent five consecutive daily sessions of dual-mode nibs with simultaneous high-frequency rtms and tdcs, whereas patients in the rtms group underwent high-frequency rtms with sham tdcs. assessments of fog, motor, ambulatory and cognitive function were performed three times: at baseline before nibs, immediately after nibs, and one week after cessation of nibs.

Eligibility criteria:
inclusion criteria: * diagnosed as parkinson's disease (pd) with freezing of gait * walk independently without walking devices exclusion criteria: * pre-existing and active major neurological diseases other than pd * a previous history of seizures * implanted metallic objects that would contraindicate rtms
to compare the efficacy and safety of using oxiris and m100 during crrt

Conditions: AKI - Acute Kidney Injury; Pneumonia

Summary: the purpose of this study aimed to compare the efficacy of oxiris (baxter) and m100 filters on il-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (crp, pct), as secondary outcomes and safety (28 days mortality as a primary outcome and coagulopathy, lifespan of filter, usage of vasopressor, clinical conditions (ventilator-free days, icu and hospital- length of stay) as a secondary outcome), clinical conditions (ventilator-free days, icu and hospital- length of stay), and mortality of patients with pneumonia-related aki.

the type of hemofilter will be decided using a simple randomization. for the intervention group, only the oxiris filter will be used during the treatment period, while for the control group, the m100 filter will be used throughout the treatment. if the filter becomes clogged within 24 hours, the investigator will replace it with the same filter as the previous one. however, if the filter becomes clogged after 24 hours and the patient still requires crrt, the investigator will replace it with m100. this change in filter type will not affect the study results, as only the blood parameters during the first 24 hours of treatment will be evaluated for objective one. the oxiris filter will be used for the first 24 hours, or whichever is longer, and will be replaced with an m100 filter if indicated for both groups. therefore, it will not affect the outcome of objective two compared to the standard arm group termination of crrt will be done according to recent studies once the patient fulfills either one or more of these criteria: urine output and serum creatinine are indicative of kidney recovery, vasopressor cessation, increased urine output ≥500ml/24h without diuretics, correction of fluid overload, hemodynamic stability and the possible need to shift to intermittent dialysis. the patient will be followed up until 28 days following icu admission. to avoid any missing data, at least 3 contact numbers will be made available. if unable to get in contact with the patient, the application status of alive or dead will be applied to a national registry.

Eligibility criteria:
inclusion criteria: * all adult patients aged\>18 years old * diagnosis of septic shock * diagnosis of kdigo stage 3 acute renal failure exclusion criteria: * moribund patient or patient that is expected to die within 72 hours * pregnancy * patient with a bleeding tendency or known allergy to heparin